The Driving Force Behind Medtronic Earnings
Tuesday before the markets opened, Medtronic (NYSE: MDT) reported better-than-expected fiscal third-quarter financial results.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 272What to Expect From Medtronic Earnings
Medical device maker Medtronic is scheduled to report its fiscal third-quarter results Tuesday before the opening bell.
Short Sellers Look Scared of Big Biotech
The short interest data are out for the January 30 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Analyst Sees BioMarin Up Another 25%
BioMarin Pharmaceutical received a favorable analyst call from Merrill Lynch in Monday.
SteadyMed Files for IPO
Specialty pharmaceutical company SteadyMed has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering.
Achillion Breaks Through Phase 2 HCV
Achillion Pharmaceuticals has announced updated interim results from an ongoing Phase 2 study and the stock saw a solid boost in Monday's trading.
Credit Suisse Gives Up on Gilead, Sort Of
Credit Suisse downgraded Gilead Sciences to Neutral and lowered its price target, citing increased competition for hepatitis C drugs.
5 Top Credit Suisse Health Care Stock Picks to Buy for 2015
24/7 Wall St. reviewed the new Credit Suisse Top Picks for 2015 report, and here are five of the top health care picks.
More Proof of Accelerating Boston Scientific Turnaround
Boston Scientific is pushing forward in its long turnaround and is gathering more speed.
Are Teva’s Earnings Good Enough?
Prior to the markets opening Thursday, Teva Pharmaceutical reported its most recent financial results.
Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines
If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the costs of some of the drugs on the market today.
Just How Bad Have Things Gotten at Myriad Genetics?
Myriad Genetics shares traded down as much as 16% Wednesday morning after the company lowered its fiscal-year guidance.
Gilead Dividend and Buyback Different From Amgen’s Strategy
Gilead Sciences has become so large and accumulated enough capital that it has decided to begin paying a dividend, a move follows Amgen.
Loss of Hep C Drug Status Weighs on Merck Earnings
Merck reported largely in-line fourth-quarter financial results Wednesday before the U.S. markets opened.
Will Increased Competition Hurt Gilead’s Outlook?
Gilead Sciences reported better-than-expected fourth-quarter results Tuesday after the markets closed.